Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Southwest Oncology Group

SWOG Southwest Oncology Group (an alliance of cancer centers that conducts national clinical trials in cancer)... [Pg.1383]

Bukowski, R. et al. Phase II study of anguidine in gastrointestinal malignancies A Southwest Oncology Group study. Cancer Treat. Rep. 66, 381, 1982. [Pg.301]

The Southwest Oncology Group (SWOG) conducted a phase II trial with continuous thoracic radiation to a total dose of 61 Gy and simultaneous daily cisplatin (5 mg/m2) and found acceptable toxicity (130). Another trial utilized a split-course of thoracic radiation therapy to a total dose of 50 Gy and simultaneous daily continuous infusion cisplatin (5 mg/m2) and found a 35 % 2-yr survival rate with relatively mild toxicity (131). Weekly doses of carboplatin were administered with continuous thoracic irradiation to a total dose of 60 Gy in a phase II trial that resulted in a 45% response rate (132). [Pg.54]

HazukaM, Crowley J, Bunn P, etal. Concurrent daily low-dose cisplatin combined with chest irradiation in locally advanced non-small cell lung cancer. Preliminary results of a Southwest Oncology Group study. Proc Amer Soc Clin Oncol 1992 11 295. [Pg.62]

Al-Sarraf M, Metch B, Kish J, et al. Platinum analogs in recurrent and advanced head and neck cancer a Southwest Oncology Group and Wayne State University Study. Cancer Treat Rep 1987 71 723-726. [Pg.171]

Kies MS, Mira JG, Crowley JJ, etal. Multimodal therapy for limited small-cell lung cancer A randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders, and with wide-field vs reduced-field radiation in partial responders A Southwest Oncology Group Study. J Clin Oncol 1987 5 592-600. [Pg.210]

Fabian C, Giri S, Estes N, et al. Adjuvant continuous infusion 5-FU, whole-abdominal radiation, and tumor bed boost in high-risk stage III colon carcinoma a Southwest Oncology Group pilot study. Int J Radiat Oncol Biol Phys 1995 32 457 164. [Pg.287]

Dalton WS, Crowley JJ, Salmon SS, et al. A phase HI randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer 1995 75(3) 815-820. [Pg.424]

Alan FL, Kenneth JK, Cheryl LW, David RH, Diane LP, Marilyn LS, Robert D, Chatchada K, Harry EH, James HD, Muhammad S, Frederick RA (2001) Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia a Southwest Oncology Group study. Blood 98 3212-3220... [Pg.245]

Macdonald, J.S., et al. (2005). A phase 11 study of farnesyl transferase inhibitor R115777 in pancreatic cancer a Southwest oncology group (SWOG 9924) study. Invest New Drugs 23 485-487. [Pg.225]

Leith C, Kopecky K, Chen I, Eijdems L, Slovak M, McConnell T, Head D, Weick J, Grever M, Appelbaum F, Wilhnan C. Frequency and clinical significance of the expression of the multidrug resistance proteins MDRl/P-glycoprotein, MRPl, and LRP in acute myeloid leukemia a Southwest Oncology Group Smdy. Blood 1999 94 1086-1099. [Pg.1961]

Dixon DO, Neilan B, Jones SE, Lipschitz DA, Miller TP, Grozea PN, Wilson, HE. Effect of age on the therapeutic outcome in advanced diffuse histiocytic lymphoma The Southwest Oncology Group experience. J Clin Oncol 1986 4 295-305. [Pg.387]

Mather FJ, Simon RM, Clark GM, Von Hoff DD. Cardiotoxicity in patients treated with mitoxantrone Southwest Oncology Group phase 11 studies. Cancer Treat Rep 1987 71(6) 609-13. [Pg.252]

Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalik A, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer a Southwest Oncology Group study. J Clin Oncol 1995 13(6) 1303-11. [Pg.1416]

Whitehead RP, Lew D, Flanigan RC, Weiss GR, Roy V, Glode ML, Dakhil SR, Crawford ED. Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma a Southwest Oncology Group study. J Immunother 2002 25(4) 352-8. [Pg.1846]

Williamson SK, Tangen CM, Maddox AM, Spiridonidis CH, Macdonald JS. Phase II evaluation of low-dose continuous 5-fluorourach and weekly cisplatin in advanced adenocarcinoma of the stomach. A Southwest Oncology Group study. Am J Chn Oncol 1995 18(6) 484-7. [Pg.2871]

Hussain M, Fisher El, Petrylak DP, O Connor J, Wood DP, Small EJ, Eisenberger MA, Crawford ED. Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer a Southwest Oncology Group Study. J CUn Oncol 2000 18(5) 1043-9. [Pg.3253]

Schroder LE, Lew D, Flanigan RC, Eisenberger MA, Seay TE, Hammond N, Needles BM, Crawford ED. Phase 11 evaluation of suramin in advanced renal cell carcinoma. A Southwest Oncology Group study. Urol Oncol 2001 6(4) 145-8. [Pg.3254]

All-Sarraf M, Fletcher W, OlshI N, Pugh R, Hewlett JS, BalduccI L, McCracken J, Padilla F. Cisplatin hydration with and without mannitol diuresis In refractory disseminated malignant melanoma a southwest oncology group study. CancerTreat Rep 1982 66 31-5. [Pg.528]

Kelly K, Crowley J, Bunn PA. Randomized phase 111 trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with non-small-cell lung cancer A Southwest Oncology Group trial. J CUn Oncol 2001 19 3210-3218. [Pg.2380]

Osborne CK, Blumenstein B, Crawford ED, et al. Combined versus sequential chemo-endocrine therapy in advanced prostate cancer Einal results of a randomized southwest oncology group smdy. J Chn Oncol 1990 8 1675-1682. [Pg.2437]

R-CHOP rimximab, cyclophosphamide hydroxydaunomycin, vincristine (Oncovin), and prednisone REAL-WHO Revised European-American Classification of Lymphoid Neoplasms and World Health Organization RICE rituximab, ifosfamide, carboplatin, and etoposide SWOG Southwest Oncology Group... [Pg.2463]

Press OW, Unger JM, Braziel RM, et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma Southwest Oncology Group Protocol S9911. Blood 2003 102 1606-1612. [Pg.2465]

Jones SE, Grozea PN, Metz EN, et al. Superiority of Adriamycin containing combination chemotherapy in the treatment of diffuse lymphoma a Southwest Oncology Group study. Cancer 1979 43 417M25. [Pg.2465]

Blayney DW, LeBlanc ML, Grogan T, et al. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol 2003 21 2466-2473. [Pg.2465]

Alberts DS, Green S, Hannigan EV, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide Final report by the Southwest Oncology Group of a phase 111 randomized trial in stages III and IV ovarian cancer [published erratum appears in J Clin Oncol 1992 10 1505]. J Clin Oncol 1992 10 706-717. [Pg.2480]

Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia a Southwest Oncology Group study. Blood 1996 88 2841-2851. [Pg.2508]

Anderson JE, Kopecky KJ, Willman CL, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin a Southwest Oncology Group study. Blood 2002 100 3869-3876. [Pg.2510]

See other pages where Southwest Oncology Group is mentioned: [Pg.458]    [Pg.21]    [Pg.182]    [Pg.184]    [Pg.194]    [Pg.274]    [Pg.310]    [Pg.317]    [Pg.332]    [Pg.479]    [Pg.215]    [Pg.2866]    [Pg.2381]    [Pg.2456]    [Pg.2465]    [Pg.2481]    [Pg.2497]    [Pg.2509]   


SEARCH



OncoLogic

Oncology

© 2024 chempedia.info